-
December 29, 2025 Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist
-
December 18, 2025 Lupin Signs Exclusive Licensing Agreement with Neopharmed for Gastroenterology Brand Plasil® in the Philippines and Brazil
-
December 17, 2025 Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab
-
December 16, 2025 Lupin Receives EIR from US FDA for its Nagpur Injectable Facility
-
December 16, 2025 Lupin Secures SBTi Validation for Emission Reduction Targets
-
December 12, 2025 Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
-
December 5, 2025 Lupin Receives Tentative Approval from U.S. FDA for Siponimod Tablets
-
December 4, 2025 Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ (Pegfilgrastim-unne) in the United States
-
December 1, 2025 Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg™ (Pegfilgrastim-unne)
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications